GRAIL Announces Positive Top-Line Results From The Galleri® PATHFINDER 2 Registrational Study

Cancer Detection and Positive Predictive Value Substantially Higher Than the Previously Published PATHFINDER Study

MENLO PARK, Calif., June 18, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced positive top-line performance and safety results from the pre-specified analysis of the first 25,578 participants in GRAIL's registrational PATHFINDER 2 study. PATHFINDER 2 was initiated in 2021 to evaluate the safety and performance of the Galleri^® multi-cancer early detection (MCED) test when added to standard of care single cancer screening in 35,878 adults over 50 years of age with no clinical suspicion of cancer. 

Read more at prnewswire.com